The latest announcement is out from HLS Therapeutics Inc ( (TSE:HLS) ).
HLS Therapeutics Inc. announced it will release its Q4 and fiscal 2024 financial results on March 13, 2025, followed by a conference call hosted by its executive team. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning within the pharmaceutical industry.
More about HLS Therapeutics Inc
HLS Therapeutics Inc. is a pharmaceutical company established in 2015, specializing in the acquisition and commercialization of late-stage development, commercial stage promoted, and established branded pharmaceutical products in North America. The company focuses on addressing unmet needs in psychiatric disorders and cardiovascular disease treatments, leveraging a management team with extensive experience in these therapeutic areas.
YTD Price Performance: 5.25%
Average Trading Volume: 37,246
Technical Sentiment Consensus Rating: Hold
Current Market Cap: C$133.8M
Find detailed analytics on HLS stock on TipRanks’ Stock Analysis page.